Radiated gold nanoparticles target cancer cell division

Oxford researchers have developed a cancer-killing combo from gold nanoparticles harboring a dose of radiation. The compound burrows into cancer cells to attack their division mechanisms, leading to cell death.

The team from the Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology initially used radiation as a tracer to monitor the particles’ infiltration of the cell. They found that the gold reached the desired target in the cell to shut down telomerase, which is a molecule on the tips of chromosomes that allows the cell to divide but breaks down over time. In cancer cells, that breakdown is obstructed, enabling the cells to proliferate freely.

The gold nanoparticles, easily absorbed by cells, reached these telomeres to deactivate the telomerase molecule in skin cancer cells, halting the cancer’s growth. And loaded with a stronger radiation dose, the particles could give even resistant cancer cells a fatal blow.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Gold has been used in medicine for many years and this research adds further insight into its potential,” CRUK CEO Harpal Kumar said. “Ensuring that treatment is accurately targeted at cancer and avoids healthy cells is the goal for much of cancer research, and this is an exciting step towards that.”

Read more on

Suggested Articles

The week’s news included a study of a Karyopharm drug in treating immunotherapy-resistant cancer and insight into how metformin promotes weight loss.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.